- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- ADVAIR DISKUS 250/50 mg BID, SEREVENT 50 mcg BID
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 639 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Florence, Alabama • Mobile, Alabama + 66 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced May 21, 2026, 7:20 PM EDT